ArticleCancer research2020
The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.International journal of clinical practice · 2022Pooled it
- Integrated multi-omics and single-cell analyses identify metabolic heterogeneity and therapeutic vulnerabilities in medullary thyroid cancer.British journal of cancer · 2026Article
- Unveiling Lipid Metabolism-Related Gene PTGDS: A Tumor Suppressor in Lung Adenocarcinoma with Therapeutic Potential.Cancers · 2026Article
- Statins targeting mevalonate-geranylgeranyl diphosphate pathway inhibit proliferation in NK/T lymphoma by promoting pyroptosis.Translational oncology · 2026Article
- Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment.Biomedicines · 2025Review
- PPP2CB aggravates atherosclerosis-related dyslipidemia via LOX-1/MAPK/ERK signaling pathway.Lipids in health and disease · 2025Article
- Refinement of MEK inhibitors.Future medicinal chemistry · 2025Article
- Proteogenomic Characterization of High-Grade Lung Neuroendocrine Carcinoma Deciphers Molecular Diversity and Potential Biomarkers of Different Histological Subtypes in Chinese Population.Research (Washington, D.C.) · 2025Article
- Mechanistic study of glutamine metabolic reprogramming driving non-small cell lung cancer progression via the FGF17-FGFR4 axis mediating epithelial-mesenchymal transition.Frontiers in molecular biosciences · 2025Article
- Is the MAPK ERK5 the nexus from FAO to NK cell-mediated metastasis immune surveillance?Frontiers in immunology · 2025Review
- Levels of serum lipids predict responses to PD-L1 inhibitors as first-line treatment in small cell lung cancer: an observational study.International journal of clinical pharmacy · 2024Observational
- Mechanisms of Abnormal Lipid Metabolism in the Pathogenesis of Disease.International journal of molecular sciences · 2024Review
- Article
- Bone and Extracellular Signal-Related Kinase 5 (ERK5).Biomolecules · 2024Review
- ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression.International journal of molecular sciences · 2024Article
- NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway.Cancer science · 2024Article
- An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma.Cell reports · 2024Article
- Natural products targeting the MAPK-signaling pathway in cancer: overview.Journal of cancer research and clinical oncology · 2024Review
- Actionable Driver Events in Small Cell Lung Cancer.International journal of molecular sciences · 2023Review
- The clinical application of atorvastatin in patients with small-cell lung cancer with dyslipidemia.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Sandra CristeaDepartment of Pediatrics, Stanford University, Stanford, California.
Garry L ColesDepartment of Pediatrics, Stanford University, Stanford, California.
Daniel HornburgDepartment of Genetics, Stanford University, Stanford, California.
Maya GershkovitzDepartment of Pediatrics, Stanford University, Stanford, California.
Julia ArandDepartment of Pediatrics, Stanford University, Stanford, California.ORCID 0000-0002-2357-1119
Siqi CaoDepartment of Pediatrics, Stanford University, Stanford, California.
Triparna SenDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Stuart C WilliamsonDepartment of Pediatrics, Stanford University, Stanford, California.ORCID 0000-0002-5209-4796
Jun W KimDepartment of Pediatrics, Stanford University, Stanford, California.
Alexandros P DrainasDepartment of Pediatrics, Stanford University, Stanford, California.
Andrew HeDepartment of Pediatrics, Stanford University, Stanford, California.
Laurent Le CamIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France.ORCID 0000-0003-0325-878X
Lauren Averett ByersDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0780-2677
Michael P SnyderDepartment of Genetics, Stanford University, Stanford, California.
Kévin ContrepoisDepartment of Genetics, Stanford University, Stanford, California.ORCID 0000-0001-9678-5161
Julien SageDepartment of Pediatrics, Stanford University, Stanford, California. julsage@stanford.edu.ORCID 0000-0002-8928-9968
Stanford Medicine · USStanford University · USThe University of Texas MD Anderson Cancer Center · USCancer Research UK Manchester Institute · GBInserm · FR
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MSpecial EquipmentP50HG007735 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2014 to 2018
$15.2MSingle-Cell Biology and Data Analysis Shared Resource (SCB-DA SR)U54CA217450 · NCI · VANDERBILT UNIVERSITY · PI WEAVER, ALISSA M · 2018 to 2022
$8.5MInvestigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategiesR35CA231997 · NCI · STANFORD UNIVERSITY · PI SAGE, JULIEN · 2019 to 2025
$6.2MStanford Training Program in Aging ResearchT32AG047126 · NIA · STANFORD UNIVERSITY · PI VYJEYANTHI S PERIYAKOIL, TONY WYSS-CORAY · 2014 to 2026
$4.3MNovel therapeutic approaches for enhancing anti-tumor immunity in SCLCU01CA213273 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2017 to 2021
$3.0MMolecular and cellular mechanisms of SCLC metastasisR01CA206540 · NCI · STANFORD UNIVERSITY · PI SAGE, JULIEN · 2016 to 2019
$1.7MNotch signaling in small cell lung carcinomaR01CA201513 · NCI · STANFORD UNIVERSITY · PI SAGE, JULIEN · 2016 to 2019
$1.5MInvestigating the Role of the Mek5-Erk5 Kinase Module in Small Cell Lung CancerF31CA206346 · NCI · STANFORD UNIVERSITY · PI CRISTEA, SANDRA · 2016 to 2018
$112kCancer Research UKNCI NIH HHS F31 CA206346NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA201513NCI NIH HHS R01 CA206540NCI NIH HHS R35 CA231997NCI NIH HHS U01 CA213273NCI NIH HHS U54 CA217450NHGRI NIH HHS P50 HG007735NIA NIH HHS T32 AG047126
Abstract
Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with dismal survival rates. While kinases often play key roles driving tumorigenesis, there are strikingly few kinases known to promote the development of SCLC. Here, we investigated the contribution of the MAPK module MEK5-ERK5 to SCLC growth. MEK5 and ERK5 were required for optimal survival and expansion of SCLC cell lines
Indexed as
AnimalsAtorvastatinCell Line, TumorCell SurvivalCholesterolGene Knockdown TechniquesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesLipid MetabolismLipidomicsLung NeoplasmsMAP Kinase Kinase 5MAP Kinase Signaling SystemMevalonic AcidMiceAtorvastatinCholesterolHMGCR protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesMAP2K5 protein, humanMAPK7 protein, humanMAP Kinase Kinase 5Mevalonic AcidMitogen-Activated Protein Kinase 7
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.